Evidence map›Paper›PMID 25288397›Full record

ArticleThe Journal of experimental medicine2014

The AP-1 transcription factor Fra1 inhibits follicular B cell differentiation into plasma cells.

Bettina Grötsch, Sebastian Brachs, Christiane Lang, Julia Luther, Anja Derer, Ursula Schlötzer-Schrehardt, Aline Bozec, Simon Fillatreau, Ingolf Berberich, Elias Hobeika and 5 more

Erratum issuedOpen access · bronzeAbstract read
In one paragraph

Article in The Journal of experimental medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 38 papers.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 55 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. FRA1 (Frontiers in cell and developmental biology · 2025
    Article
  9. FOSMolecular therapy. Oncology · 2024
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

  • Erratum issued
5 · Who and what money

Authors and funding

15 authors at 7 institutions in 3 countries.

Bettina GrötschDivision of Molecular Immunology, Nikolaus Fiebiger Center, Department of Internal Medicine III, Department of Radiation Oncology, Division of Ophthalmology, Department Kopfklinik, University of Erlangen-Nuremberg, D91054 Erlangen, Germany.
Sebastian BrachsDivision of Molecular Immunology, Nikolaus Fiebiger Center, Department of Internal Medicine III, Department of Radiation Oncology, Division of Ophthalmology, Department Kopfklinik, University of Erlangen-Nuremberg, D91054 Erlangen, Germany.
Christiane LangDivision of Molecular Immunology, Nikolaus Fiebiger Center, Department of Internal Medicine III, Department of Radiation Oncology, Division of Ophthalmology, Department Kopfklinik, University of Erlangen-Nuremberg, D91054 Erlangen, Germany.
Julia LutherDivision of Molecular Immunology, Nikolaus Fiebiger Center, Department of Internal Medicine III, Department of Radiation Oncology, Division of Ophthalmology, Department Kopfklinik, University of Erlangen-Nuremberg, D91054 Erlangen, Germany Institute for Osteology and Biomechanics, University Medical Center Hamburg-Eppendorf, D20246 Hamburg, Germany.
Anja DererDivision of Molecular Immunology, Nikolaus Fiebiger Center, Department of Internal Medicine III, Department of Radiation Oncology, Division of Ophthalmology, Department Kopfklinik, University of Erlangen-Nuremberg, D91054 Erlangen, Germany Division of Molecular Immunology, Nikolaus Fiebiger Center, Department of Internal Medicine III, Department of Radiation Oncology, Division of Ophthalmology, Department Kopfklinik, University of Erlangen-Nuremberg, D91054 Erlangen, Germany.
Ursula Schlötzer-SchrehardtDivision of Molecular Immunology, Nikolaus Fiebiger Center, Department of Internal Medicine III, Department of Radiation Oncology, Division of Ophthalmology, Department Kopfklinik, University of Erlangen-Nuremberg, D91054 Erlangen, Germany.
Aline BozecDivision of Molecular Immunology, Nikolaus Fiebiger Center, Department of Internal Medicine III, Department of Radiation Oncology, Division of Ophthalmology, Department Kopfklinik, University of Erlangen-Nuremberg, D91054 Erlangen, Germany.
Simon FillatreauGerman Rheumatism Research Center (DRFZ), a Leibniz Institute, D10117 Berlin, Germany.
Ingolf BerberichInstitute for Virology und Immunobiology, University of Würzburg, D97078 Würzburg, Germany.
Elias HobeikaBIOSS Centre for Biological Signalling Studies, Department of Molecular Immunology, Biology III, Faculty for Biology, and Max Planck Institute of Immunobiology and Epigenetics, University of Freiburg, D79108 Freiburg, Germany.
Michael RethBIOSS Centre for Biological Signalling Studies, Department of Molecular Immunology, Biology III, Faculty for Biology, and Max Planck Institute of Immunobiology and Epigenetics, University of Freiburg, D79108 Freiburg, Germany.
Erwin F WagnerSpanish National Cancer Center, Genes, Development and Disease Group, E28029 Madrid, Spain.
Georg SchettDivision of Molecular Immunology, Nikolaus Fiebiger Center, Department of Internal Medicine III, Department of Radiation Oncology, Division of Ophthalmology, Department Kopfklinik, University of Erlangen-Nuremberg, D91054 Erlangen, Germany.
Dirk MielenzDivision of Molecular Immunology, Nikolaus Fiebiger Center, Department of Internal Medicine III, Department of Radiation Oncology, Division of Ophthalmology, Department Kopfklinik, University of Erlangen-Nuremberg, D91054 Erlangen, Germany j.david@uke.de dmielenz@molmed.uni-erlangen.de.
Jean-Pierre DavidDivision of Molecular Immunology, Nikolaus Fiebiger Center, Department of Internal Medicine III, Department of Radiation Oncology, Division of Ophthalmology, Department Kopfklinik, University of Erlangen-Nuremberg, D91054 Erlangen, Germany Institute for Osteology and Biomechanics, University Medical Center Hamburg-Eppendorf, D20246 Hamburg, Germany j.david@uke.de dmielenz@molmed.uni-erlangen.de.
Friedrich-Alexander-Universität Erlangen-Nürnberg · DERadiation Oncology Institute · USMax Planck Institute of Immunobiology and Epigenetics · DEUniversity Medical Center Hamburg-Eppendorf · DEGerman Rheumatism Research Centre · DESpanish National Cancer Research Centre · ESUniversity of Würzburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The cornerstone of humoral immunity is the differentiation of B cells into antibody-secreting plasma cells. This process is tightly controlled by a regulatory gene network centered on the transcriptional repressor B lymphocyte-induced maturation protein 1 (Blimp1). Proliferation of activated B cells is required to foster Blimp1 expression but needs to be terminated to avoid overshooting immune reactions. Activator protein 1 (AP-1) transcription factors become quickly up-regulated upon B cell activation. We demonstrate that Fra1, a Fos member of AP-1, enhances activation-induced cell death upon induction in activated B cells. Moreover, mice with B cell-specific deletion of Fra1 show enhanced plasma cell differentiation and exacerbated antibody responses. In contrast, transgenic overexpression of Fra1 blocks plasma cell differentiation and immunoglobulin production, which cannot be rescued by Bcl2. On the molecular level, Fra1 represses Blimp1 expression and interferes with binding of the activating AP-1 member c-Fos to the Blimp1 promoter. Conversely, overexpression of c-Fos in Fra1 transgenic B cells releases Blimp1 repression. As Fra1 lacks transcriptional transactivation domains, we propose that Fra1 inhibits Blimp1 expression and negatively controls plasma cell differentiation through binding to the Blimp1 promoter. In summary, we demonstrate that Fra1 negatively controls plasma cell differentiation by repressing Blimp1 expression.

Indexed as

AnimalsApoptosisB-LymphocytesCell DifferentiationFos-Related Antigen 1Gene Expression RegulationImmunity, HumoralImmunomodulationLymphocyte ActivationMiceMice, TransgenicPlasma CellsPositive Regulatory Domain I-Binding Factor 1Promoter Regions, GeneticProtein BindingProto-Oncogene Proteins c-fosFos-Related Antigen 1Positive Regulatory Domain I-Binding Factor 1Prdm1 protein, mouseProto-Oncogene Proteins c-fosTranscription Factors

Identifiers

PMID25288397
PMCPMC4203943
OpenAlexW2103040857

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.